Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Drug Discovery|
|State||Published - Oct 2011|
ASJC Scopus subject areas
- Drug Discovery